CONTRIBUTORS

p. 588-592 June 2019, Vol.25, No.3 doi: 10.1212/01.CON.0000558244.88987.2e
CONTRIBUTORS
BROWSE ARTICLES

Dean M. Wingerchuk, MD, MSc, FRCPC, FAAN, Guest Editor

Professor and Chair, Department of Neurology, Mayo Clinic, Phoenix/Scottsdale, Arizona

Relationship Disclosure: Dr Wingerchuk serves as co–editor-in-chief of The Neurologist; as a consultant for Alexion, Celgene Corporation, and Novartis AG; and as an adjudication committee member for MedImmune. Dr Wingerchuk receives research/grant support from Alexion and Terumo BCT, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Wingerchuk reports no disclosure.

James D. Bowen, MD

Medical Director, Multiple Sclerosis Center, Swedish Neuroscience Institute; Clinical Associate Professor, Neurology, University of Washington, Seattle, Washington

Relationship Disclosure: Dr Bowen has served as a consultant for Biogen; Celgene Corporation; EMD Serono, Inc; Genentech, Inc; and Novartis AG and has received personal compensation for speaking engagements from Biogen; EMD Serono, Inc; Genentech, Inc; and Novartis AG. Dr Bowen receives research/grant support from Alexion; Alkermes; Biogen; Celgene Corporation; Genentech, Inc; the National Institute of Allergy and Infectious Diseases (UM1AI110557); the National Institutes of Health /National Institute on Aging (U01AG006781); the National Institutes of Health/National Institute of Allergy and Infectious Diseases (N01AI15416); the National Institute of Neurological Disorders and Stroke (U10NS077309); and Sanofi Genzyme.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Bowen discusses the unlabeled/investigational use of cyclophosphamide, high-dose immunosuppressive therapy with stem cell transplantation, and rituximab for the treatment of highly aggressive multiple sclerosis.

Tanuja Chitnis, MD, FAAN

Professor of Neurology, Harvard Medical School; Senior Neurologist, Brigham and Women’s Hospital and Massachusetts General Hospital; Director, Partners Pediatric Multiple Sclerosis Center, MassGeneral Hospital for Children; Director, Translational Neuroimmunology Research Center, Brigham and Women’s Hospital, Boston, Massachusetts

Relationship Disclosure: Dr Chitnis serves on scientifi c advisory boards for Biogen, Celgene Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, and Sanofi Genzyme and as a consultant for Biogen. Dr Chitnis receives research/grant support from the Consortium of Multiple Sclerosis Centers; the Department of Defense; EMD Serono, Inc; the Guthy-Jackson Charitable Foundation; Mallinckrodt Pharmaceuticals; the National Institutes of Health; the National Multiple Sclerosis Society; Novartis AG; Octave Bioscience; and Verily Life Sciences LLC.

Unlabeled Use of Products/Investigation Use Disclosure: Dr Chitnis discusses the unlabeled/investigational use of glatiramer acetate, interferon beta, natalizumab, and rituximab for pediatric multiple sclerosis and mycophenolate mofetil for myelin oligodendrocyte glycoprotein antibody–associated disorders and neuromyelitis optica spectrum disorder in children.

John R. Corboy, MD, FAAN

Professor, Neurology Codirector, Rocky Mountain Multiple Sclerosis Center at University of Colorado, University of Colorado School of Medicine, Aurora, Colorado

Relationship Disclosure: Dr Corboy serves as editor of Neurology Clinical Practice, as a consultant for a legal matter for Mylan NV, and on the research steering committee for Novartis AG. Dr Corboy has received personal compensation for speaking engagements from PRIME Education, LLC, and the Rocky Mountain Multiple Sclerosis Center and receives research/grant support from MedDay Pharmaceuticals, the National Multiple Sclerosis Society, Novartis AG, and the Patient-Centered Outcomes Research Institute. Dr Corboy has served as a consultant on medicolegal proceedings for medical malpractice.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Corboy discusses the unlabeled/investigational use of cyclophosphamide and rituximab for the treatment of multiple sclerosis

Eoin P. Flanagan, MBBCh

Consultant in Neurology and Laboratory Medicine and Pathology; Associate Professor of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Relationship Disclosure: Dr Flanagan receives research/grant support from MedImmune/Viela Bio.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Flanagan discusses the unlabeled/investigational use of azathioprine, cetirizine, corticosteroids, eculizumab, inebilizumab, IV immunoglobulin, methotrexate, mycophenolate mofetil, plasma exchange, rituximab, SA237, sivelestat, and tocilizumab for the treatment of neuromyelitis optica spectrum disorder and other non–multiple sclerosis central nervous system inflammatory diseases.

Robert H. Gross, MD

Assistant Professor of Neurology, University of Colorado Anschutz Medical Campus, Aurora, Colorado

Relationship Disclosure: Dr Gross reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gross discusses the unlabeled/investigational use of cyclophosphamide and rituximab for the treatment of multiple sclerosis.

Orhun H. Kantarci, MD

Associate Professor of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Relationship Disclosure: Dr Kantarci serves as a reviewer for Neurology and receives research/grant support from Biogen.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kantarci reports no disclosure.

Annette M. Langer-Gould, MD, PhD

Regional Lead for Clinical and Translational Neuroscience, Kaiser Permanente/Southern California Permanente Medical Group, Pasadena, California

Relationship Disclosure: Dr Langer-Gould receives research/grant support from the National Multiple Sclerosis Society and the Patient-Centered Outcomes Research Institute and has provided expert legal testimony regarding vaccination.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Langer-Gould discusses the unlabeled/investigational use of corticosteroids and plasma exchange to treat multiple sclerosis relapse during pregnancy, gabapentin to treat neuropathic pain, natalizumab to treat multiple sclerosis during pregnancy, and rituximab to treat multiple sclerosis.

Luanne M. Metz, MD, FRCPC

Professor, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary; Coleader, Multiple Sclerosis Program, Hotchkiss Brain Institute, Calgary Alberta, Canada

Relationship Disclosure: Dr Metz receives research/grant support from Alberta Innovates Health Solutions (201300669) and the Multiple Sclerosis Society of Canada.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Metz was the principal investigator on a phase 3 study on the use of minocycline for the treatment of clinically isolated syndrome.

Ellen M. Mowry, MD, MCR, FAAN, FANA

Associate Professor of Neurology and Epidemiology, Johns Hopkins University, Baltimore, Maryland

Relationship Disclosure: Dr Mowry serves as an editor for Frontiers in Neuroepidemiology, ISRN Neuroscience, and Neuroscience Journal. Dr Mowry receives research/grant support from Biogen, the Department of Defense, the National Multiple Sclerosis Society, Sanofi Genzyme, and Sun Pharmaceuticals Industries Ltd and publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Mowry reports no disclosure.

Bardia Nourbakhsh, MD, MAS

Assistant Professor of Neurology, Johns Hopkins University, Baltimore, Maryland

Relationship Disclosure: Dr Nourbakhsh has served on a scientifi c advisory board for Jazz Pharmaceuticals Inc and has received research/grant support from the National Multiple Sclerosis Society and the Patient-Centered Outcomes Research Institute.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Nourbakhsh reports no disclosure.

Daniel Ontaneda, MD

Assistant Professor of Medicine/Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Staff Neurologist, Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, Ohio

Relationship Disclosure: Dr Ontaneda serves as a consultant for Biogen; Genentech, Inc; and Sanofi Genzyme and receives research/grant support from Genentech, Inc; the National Institutes of Health; the National Multiple Sclerosis Society; Novartis AG; the Patient-Centered Outcomes Research Institute; Race to Erase; and Sanofi Genzyme.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Ontaneda discusses clinical trial results for biotin, fi ngolimod, ibudilast, mycophenolate mofetil, natalizumab, and rituximab for the treatment of progressive multiple sclerosis.

Alexander D. Rae-Grant, MD, FRCPC, FAAN

Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Staff Neurologist, Cleveland Clinic, Cleveland, Ohio

Relationship Disclosure: Dr Rae-Grant serves as deputy editor for DynamedPlus.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rae-Grant reports no disclosure.

Pavle Repovic, MD, PhD

Medical Director for Neurology Research, Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington

Relationship Disclosure: Dr Repovic has served as a consultant for Biogen; EMD Serono, Inc; Genentech, Inc; Sanofi Genzyme; and Teva Pharmaceutical Industries Ltd and has received personal compensation for speaking engagements from Biogen; EMD Serono, Inc; Genentech, Inc; and Teva Pharmaceutical Industries Ltd. Dr Repovic receives research/grant support from Alexion, the National Institutes of Health (5U10NS077309), Novartis AG, and Genentech, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Repovic reports no disclosure.

Andrew J. Solomon, MD

Associate Professor of Neurological Sciences; Division Chief, Multiple Sclerosis, Larner College of Medicine at The University of Vermont, Burlington, Vermont

Relationship Disclosure: Dr Solomon has served as a consultant for Biogen and EMD Serono, Inc, and has received research/grant support from Biogen and personal compensation for speaking engagements from Med Learning Group, the National Multiple Sclerosis Society, and RMEI Medical Education.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Solomon reports no disclosure.

W. Oliver Tobin, MBBCh, BAO, PhD

Consultant, Division of Multiple Sclerosis; Assistant Professor of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Relationship Disclosure: Dr Tobin receives research/grant support from Mallinckrodt Pharmaceuticals.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Tobin discusses the unlabeled/investigational use of amantadine, armodafi nil, and modafi nil for fatigue; lacosamide, lamotrigine, and oxcarbazepine for paroxysmal symptoms; gabapentin for restless legs syndrome and spasticity; and nabiximols, oral cannabis extract, and synthetic tetrahydrocannabinol for the treatment of spasticity.

Self-Assessment and CME Test Writers

D. Joanne Lynn, MD, FAAN

Associate Dean for Student Life, Clinical Professor of Neurology, The Ohio State University College of Medicine, Columbus, Ohio

Relationship Disclosure: Dr Lynn receives book royalties from Lippincott Williams & Wilkins and holds stock in Abbott Laboratories; AbbVie Inc; Amgen Inc; Bristol-Myers Squibb Company; CVS Health Corporation; Express Scripts Holding Company; General Electric; Merck & Co, Inc; and Zimmer Biomet.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Lynn reports no disclosure.

Allison L. Weathers, MD, FAAN

Associate Chief Medical Information Offi cer, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Relationship Disclosure: Dr Weathers serves on the editorial board of Continuum and as chair of the adult neurosciences specialty steering board for Epic.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Weathers reports no disclosure.

© 2019 American Academy of Neurology.